-
New Publication: Eliquis (Apixaban) is Effective and Safe in DVT and PE
-
Top 10 Publications on Thrombosis and Anticoagulation from 2012
Stephan Moll writes… 2012 has been a year with significant progress in the field of venous thromboembolism and anticoagulation. The three most noteworthy, clinically relevant developments were probably (a) the publication of the new ACCP (American College of Chest Physician) guidelines on antithrombotic therapy in February 2012; (b) The FDA-approval of rivaroxaban (Xarelto) in November 2012 for the acute…
-
TTP with I.V. Use of Pain Medication OpanaER
Stephan Moll, MD writes… The CDC published an alert on Oct 26th, 2012, that they are investigating 12 cases of TTP (thrombotic thrombocytopenic purpura) in drug users who injected intravenously the opioid pain medication Opana ER® (oxymorphone extended-release), a medication made as a tablet and meant for oral use. The tablet was pulverized by the drug…
-
Ischemic Colitis and Thrombophilia
Stephan Moll, MD writes… Ischemic colitis is an uncommon and typically benign disorder. For mostly unclear reasons, multiple small vessels in the colonic wall have decreased perfusion or become occluded, resulting in patchy, superficially ulcerated areas. Typically, no surgical intervention is needed and the patient recovers spontaneously within 1-2 weeks. Often patients have only one episode. Few…
-
Recovery After a DVT or PE
-
DVT in Young Adults – IVC Abnormalities
-
New ACCP Guidelines – DVT and PE: Highlights and Summary
-
Pulmonary Hypertension after PE – CTEPH
Pulmonary hypertension affects up to 4 % of PE patient and typically occurs within the first 2 years after a PE. It is defined as a mean pulmonary artery pressure of ≥ 25 mm Hg by right heart catheterization, with normal pulmonary capillary wedge pressure, and elevated pulmonary vascular resistance. Pulmonary hypertension occurring after an…
